Survey: Fertility and the use of Immune Checkpoint Inhibitor Therapy (Survey from Royal Marsden Hospital)
Immune checkpoint inhibitors, such as atezolizumab, nivolumab and pembrolizumab have transformed the treatment landscape for many cancers.
Cancers such as melanoma and Lynch-syndrome related tumours necessitating immune checkpoint inhibitors are prescribed for both young people, and people who are anticipated to live many decades. For example, nearly a third of women who are diagnosed with melanoma are of childbearing age.
Younger patients with a good prognosis are potentially still suitable to consider conception and childbirth following on from their systemic therapies.
Previous retrospective data investigated the fertility effects of these therapies but there continues to be a lack of evidence in how treatments may affect long-term fertility goals.
It is recognised that immune checkpoint inhibitors may be given later down the line, depending on the tumour stream where fertility issues may be multifactorial or not applicable depending on specific patient factors.
The purpose of this survey is to detect how fertility with checkpoint inhibitor therapies is approached across the UK and to understand the variations in practice.
The survey will take 5 to 10 mins to complete. The survey closes on Friday 19th of September.
Thank you for your participation, your responses will be valuable in identifying key areas where additional research may be required or if a standardised UK guideline may be helpful.
The link to the survey can be found here: Survey Link: Fertility and the use of immunotherapy checkpoint inhibitors, or alternatively, you can use this QR code below:
